# Junta clínica — PT-pseudo_d49b896a09e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d49b896a09e6",
  "pid": "PT-pseudo_d49b896a09e6",
  "task": 1,
  "psa": 6.7,
  "age": 67,
  "months": 1,
  "pirads": "4",
  "psad": 0.2,
  "psav": 1.78,
  "psap": 4.4,
  "vol": 36.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7934635,
  "medhx": "Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)",
  "meds": "rosuvastatin, aspirin 80 mg, atorvastatin",
  "notes": "PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Coronary artery disease",
    "Obesity (BMI >30)"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "178 cm",
    "bmi": "29.4",
    "bp": "146/77 mmHg",
    "hr": "77 bpm",
    "smoking": "Current smoker (17 pack-yr)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "An upward PSA trend alongside a previously positive biopsy necessitates urological review."
    },
    {
      "s": "History",
      "t": "A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly."
    }
  ],
  "occupation": "retired warehouse worker",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Ophthalmology — cataract review"
  ],
  "alcohol": "19 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "UMCG (Groningen)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d49b896a09e6
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 4.4 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7934635 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Current medication: rosuvastatin, aspirin 80 mg, atorvastatin
  - Allergies: NKA
  - Additional notes: PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.

Vitals: weight 93 kg, height 178 cm, BMI 29.4, BP 146/77 mmHg, HR 77 bpm. Smoking: Current smoker (17 pack-yr).

Chief complaint: An upward PSA trend alongside a previously positive biopsy necessitates urological review.

History: A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable.

Physical examination: DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly.

Patient info: retired warehouse worker; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 19 units / week; exercise Running 3x/week, 5 km; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.74
  uncertainty  +/- 0.12 epistemic (95% band 0.51-0.98); among patients I cannot tell apart the outcome was 0.82 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 4, PSA 6.7, PSAD 0.2, age 67, DRE Normal -> BIOPSY (borderline). He wrote: "Active surveillance, only one previous biopsy 2 yrs ago. Stable findings (stable PIRADS4, slightly increasing PSA) -> borderline indication for biopsy. As only one previ…"
  2. distance 0.72: PI-RADS 4, PSA 6.8, PSAD 0.2, age 62, DRE Normal -> DEFER (borderline). He wrote: "All depends if the lesion has grown in size since 2024. If stable no biopsy , if increased in size I will do a biopsy."
  3. distance 0.79: PI-RADS 4, PSA 5.2, PSAD 0.151, age 68, DRE Normal -> BIOPSY (uncertain). He wrote: "Again missing earlier ISUP grading and if the PIRADS 4 lesion is stabile or growing"

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: vol=important, fh=noted, bx=important, dre=important, age=important, pirads=important, comorbidity=noted, psa=noted, psad=important.
HOW SURE HE USUALLY IS: borderline.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a repeat biopsy may be mandated if there is a lesion on MRI that mandates it to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled because the guideline makes decisive that the prior positive biopsy, combined with the documented grade and surveillance history, is what decides the next step. The guideline does not provide a threshold that makes the panel variables like prior grade or surveillance history irrelevant.

WHAT WE STILL NEED
The guideline requires information on the documented grade of the prior biopsy and the number and dates of biopsy sessions in the notes to decide.
Prior biopsy status is documented as "Positive" on the panel, which is the fact.
The number and dates of biopsy sessions are not documented in the provided panel, which is a finding.
Whether he is on a surveillance protocol with a confirmatory biopsy due is not documented in the provided panel, which is a finding.
The PSA value is 6.7 ng/mL, which is the value on the panel, and the guideline requires information on PSA-D to determine if it is below 0.15 ng/mL/cc.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade and surveillance status from the previous notes, as the panel variables do not settle the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, and is there extraprostatic extension?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the documented Gleason or ISUP grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What is the free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade of the prior positive biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Is the PSA density below 0.15 ng/mL/cc?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size is approximately "12 x 8 mm" in the left peripheral zone at the mid-gland level, and there is "no seminal vesicle invasion or extraprostatic extension".
psa_trend
The trend of the serial PSA values is from "3.0 ng/mL" on "Oct 2023" to "6.7 ng/mL" on "Jan 2025".
previous_notes
The documented Gleason or ISUP grade of the prior biopsy is "Gleason 6", there has been "one" biopsy session on "not recorded" dates, and the surveillance protocol status is "not recorded".
laboratory_results
The free-PSA fraction is "15%", renal function is "eGFR >60 mL/min/1.73m2", and haemoglobin is "14.4 g/dL".

WHAT I DID NOT OPEN
nothing

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS score of "4" on the mpMRI report.
PSA trend shows an upward trajectory from "3.0 ng/mL" to "6.7 ng/mL".
AGAINST sampling this patient now
Prior biopsy yielded a "Gleason 6" diagnosis.
Surveillance protocol status is "not recorded".

WHERE THIS LEANS
The findings suggest a need for further clarification regarding the prior biopsy grade and surveillance status, which are the key missing pieces for a definitive decision.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.70 ng/mL over 4 points spanning 15 months; velocity +2.95 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 8.9 ng/mL, conformal 95% band 2.6-31.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.78
  uncertainty  +/- 0.11 epistemic (95% band 0.56-1.00), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.74  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.78  ('firm' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.94  (identical panel in the series)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: borderline. Weights it expects: vol=important, fh=noted, bx=important, dre=important, age=important, pirads=important, comorbidity=noted, psa=noted, psad=important.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—did not fully answer the moderator's questions. Specifically, the previous_notes stated the Gleason grade was "Gleason 6," but the number and dates of biopsy sessions and surveillance protocol status were explicitly "not recorded."

ALIGNMENT WITH THE PANEL
The panel protocol concluded with BIOPSY based on the EXPERT-LIBRARY precedent, which is supported by the retrieved finding that the prior biopsy yielded a "Gleason 6" diagnosis, as noted in the previous_notes.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade of the prior positive biopsy? Answered by the registrar: "Gleason 6".
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? Answered by the registrar: "one biopsy session on not recorded dates, and the surveillance protocol status is not recorded."

WHAT CARRIES WEIGHT, AND WHY
The documented Gleason 6 diagnosis carries significant weight as it is a key factor in determining the next step, as noted by the registrar. The lack of documented surveillance protocol status is a critical missing piece that the guideline requires for a definitive decision.

MY SUGGESTION TO THE CHAIR
Given the panel's strong consensus and the retrieved finding of a Gleason 6 diagnosis, the path forward should be to proceed with a biopsy to clarify the surveillance status and lesion behavior.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

Given the prior positive biopsy yielded a Gleason 6 diagnosis, and the surveillance protocol status was not recorded, a confirmatory biopsy is indicated to clarify the current disease status. This decision is supported by the expert consensus and the retrieved finding of the Gleason 6 grade, which overrides the panel's reliance on the identical precedent. The evidence converged on the need for further clarification regarding the surveillance status and lesion behavior.

What carried weight: vol=important, bx=important, dre=important, age=important, pirads=important, comorbidity=noted, psa=noted, psad=important
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
